Kiadis Pharma launches a private placement of approximately 2.25 million new shares

Amsterdam-Duivendrecht, The Netherlands, October 9, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations safer and more effective for patients suffering from blood cancers and inherited blood disorders, today announces the launch of an undocumented private placement of approximately 2.25 million new shares to institutional investors, representing approximately 15.0% of the Company’s current issued share capital (the “Placing”). The Company retains the option to increase the number of shares to be sold. Kiadis Pharma intends to use the net proceeds of the Placing to:
advance the Phase III international, randomized, controlled, multicentre clinical trial for ATIR101TM in the United States, Canada and Europe;
– secure additional manufacturing capacity at vendors and lease its own commercial manufacturing facility;
– prepare Kiadis Pharma for launch of ATIR101TM in the EU in 2019 by investing in medical affairs, market access preparation and re-imbursement discussions;
– pursue ATIR201 and a new study combining ATIR101TM with the Baltimore protocol and/or another T-cell depleted hematopoietic stem cell transplantation;
– expand the organization to accommodate the increased number of activities;
– apply funds for debt repayment, capital expenditure, general and administrative expenses, general corporate purposes in line with Kiadis Pharma’s strategy and other working capital needs.
The new shares will be placed with institutional investors through an accelerated bookbuilding process and the subscription price and the number of shares to be issued in the Placing will be determined through this process. The bookbuilding period for the Placing will commence today with immediate effect and will close at short notice.
In relation to the Placing, the Company has, subject to customary exemptions, agreed to a lock-up undertaking for a period of 90 calendar days after the settlement date on future share issuances. In addition, and also subject to customary exemptions, the two largest shareholders of the Company (funds represented by and/or affiliated with Life Sciences Partners and Draper Esprit, together representing 51.0% of the share capital of the Company) as well as all members of the Company’s Management Board and Supervisory Board have agreed to a lock-up undertaking for a period of 90 calendar days after the settlement date on future share disposals. Kreos Capital has agreed to a lock-up undertaking for a period of 90 calendar days after the settlement date with respect to the warrants that were issued by the Company to Kreos Capital on 17 August 2017.
The Company will announce the final number of new shares placed and the subscription price in the Placing in a subsequent press release expected to be published before the beginning of trading on Euronext Amsterdam and Brussels on Tuesday 10 October 2017.
Jefferies International Limited is acting as Sole Bookrunner and Canaccord Genuity Limited and Oppenheimer & Co. Inc. are acting as Lead Managers in connection with the Placing. Chardan and Saola Healthcare Partners are acting as financial advisors to the Company.

About Kiadis Pharma
Kiadis Pharma is focused on cell-based immunotherapy products, as an adjunctive to a haploidentical hematopoietic stem cell transplantation (HSCT), for the treatment of blood cancers and inherited blood disorders. The Company’s product candidates have the potential to make allogeneic HSCT safer and more effective for patients.
Based on the positive results from the single dose Phase II trial with lead product ATIR101TM in patients with blood cancer, the Company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in April 2017, for approval of ATIR101TM across the European Union as an adjunctive treatment in HSCT for malignant disease. In addition, Kiadis Pharma has received regulatory approval in various countries to start dosing patients in a Phase III trial with ATIR101TM that will be performed across Europe and North America. ATIR101TM has been granted Orphan Drug Designations both in the US and Europe. In September 2017 the US Food and Drug Administration (FDA) granted ATIR101TM the Regenerative Medicine Advanced Therapy (RMAT) designation.
The Company’s second product candidate, ATIR201TM, will address beta thalassemia, an inherited blood disorder.
Kiadis Pharma was granted an Advanced Therapy Medicinal Product (ATMP) certificate for manufacturing quality and non-clinical data by the EMA.
The Company’s shares are listed on Euronext Amsterdam and Euronext Brussels. Company website: www.kiadis.com

Leave a comment

Your email address will not be published.